Paraprotein-Related Disease

The contract between this chapter and the reader.

1. 1. Explain how monoclonal proteins injure the kidney and the MGRS concept.
2. 2. Recognise myeloma cast nephropathy.
3. 3. Recognise AL amyloidosis and light-chain deposition disease.
4. 4. Recognise cryoglobulinemic glomerulonephritis.
5. 5. Detect the paraprotein (SPEP/UPEP, free light chains).
6. 6. Use biopsy to define the renal lesion and link it to the clone.
7. 7. Treat the clone (clone-directed therapy).
8. 8. Manage myeloma cast nephropathy urgently.
9. 9. Apply the ‘treat the clone’ principle (MGRS).

A sixty-second reading. Each bullet stands alone.

• Monoclonal proteins from a clonal B-cell or plasma-cell population injure the kidney in several distinct ways.
• Monoclonal gammopathy of renal significance (MGRS) is a small clone that causes kidney disease despite not meeting myeloma criteria.
• In MGRS, the kidney damage — not the tumour burden — drives treatment.
• Myeloma cast nephropathy is acute kidney injury from free light chains precipitating as casts in the distal tubule.
• AL amyloidosis deposits light-chain fibrils causing nephrotic syndrome (Congo-red positive).
• Light-chain deposition disease deposits non-fibrillar light chains, causing nodular glomerulosclerosis.
• Cryoglobulinemic GN is an immune-complex MPGN with low complement, often hepatitis-C-associated.
• The paraprotein is detected by serum and urine electrophoresis, immunofixation, and serum free light chains.
• Biopsy defines the renal lesion and confirms it derives from the monoclonal protein.
• The marrow characterises the clone, guiding clone-directed therapy.
• The treatment of paraprotein kidney disease is to treat the clone, reducing the pathogenic protein.
• Myeloma cast nephropathy needs urgent anti-myeloma therapy to lower light chains, plus supportive care.
• A monoclonal protein with kidney disease means treat the clone, whatever the tumour burden.

The medical core. An expert should agree paraprotein-related kidney disease is fully covered here.

Why it matters at the bedside

Amonoclonal protein in the blood is more than a haematology number — it can attack the kidney in half a dozen different ways, and the one idea that ties them together is liberating: treat the clone making the protein, and the kidney often follows. The corollary, the MGRS concept, is just as important: a ‘small’ clone that damages the kidney still needs treating.

The unifying concept and MGRS

• The unifying idea is that a monoclonal protein — a light chain or whole immunoglobulin from a clonal B-cell or plasma-cell population — injures the kidney, in several distinct patterns. The crucial reframing is monoclonal gammopathy of renal significance (MGRS): a clone too small to meet myeloma criteria can still cause serious kidney disease, and in that case the kidney damage, not the tumour burden, drives the decision to treat. ‘MGUS’ is no longer ‘undetermined significance’ once the kidney is involved.

Myeloma cast nephropathy

• Myeloma cast nephropathy — ‘myeloma kidney’ — is the classic acute kidney injury of multiple myeloma: a flood of free light chains precipitates with Tamm-Horsfall protein in the distal tubule, forming obstructing casts. It is a tubular, not glomerular, lesion. Its treatment is urgent reduction of the light chains by anti-myeloma therapy, alongside supportive care (hydration, stopping nephrotoxins, treating hypercalcemia) — and the kidney can recover if the light chains fall fast enough.

AL amyloidosis and light-chain deposition disease

• Two deposition diseases sit beside cast nephropathy. AL amyloidosis (the amyloid of the diabetic-and-other chapter) deposits light-chain-derived fibrils that are Congo-red positive, presenting with nephrotic syndrome. Light-chain deposition disease (the commonest monoclonal immunoglobulin deposition disease) deposits non-fibrillar, Congo-red-negative light chains along basement membranes, producing nodular glomerulosclerosis with proteinuria and progressive CKD. Both are treated by treating the clone.

Cryoglobulinemic GN

• Cryoglobulinemic glomerulonephritis is the immune-complex face of the monoclonal kidney: cryoglobulins (monoclonal, or mixed and often hepatitis-C-associated) deposit and produce a membranoproliferative pattern with a low complement (the complement chapter), often with systemic vasculitis and palpable purpura. It is treated by addressing its cause — hepatitis C antivirals, clone-directed therapy — with immunosuppression or plasma exchange for severe disease.

Detecting the paraprotein

• The diagnostic first step is to find the monoclonal protein: serum and urine protein electrophoresis, immunofixation (which confirms and types it), and serum free light chains with the kappa/lambda ratio (which quantify it and track the response to treatment). A bone marrow examination characterises the clone. Without detecting the paraprotein, the renal lesion's cause is missed.

Biopsy and linking to the clone

• The renal biopsy defines the lesion — cast, amyloid, deposition, cryoglobulinemic, or other — with Congo red for amyloid and electron microscopy distinguishing fibrillar from non-fibrillar deposits. Crucially, it demonstrates light-chain restriction (kappa or lambda), confirming that the lesion derives from the monoclonal protein. This linkage — lesion to clone — is what establishes MGRS and justifies clone-directed treatment.

Treating the clone

• The treatment, across the spectrum, is to treat the clone — reducing the pathogenic protein at its source. The regimen is matched to the clone: anti-plasma-cell therapy (for example, bortezomib-based) for plasma-cell clones, and anti-B-cell therapy (for example, rituximab-based) for B-cell or lymphoplasmacytic clones. This is co-managed with haematology, and — the MGRS principle — a small clone causing kidney disease is treated even though its tumour burden would not, by itself, warrant therapy.

Managing myeloma cast nephropathy urgently

• Cast nephropathy is the most time-pressured of these diseases: the obstructing casts and ongoing light-chain toxicity destroy the kidney unless the light chains are brought down quickly. So anti-myeloma therapy is started urgently to cut the light-chain production, with supportive measures (volume, avoiding nephrotoxins and further precipitation, treating hypercalcemia) — the faster the light chains fall, the better the chance of renal recovery.

The ‘treat the clone’ principle

• The chapter resolves to a single, portable rule: a monoclonal protein plus kidney disease means treat the clone, whatever the tumour burden. Identify the protein (electrophoresis, free light chains), define the lesion (biopsy, with light-chain restriction), and treat the clone making it. It is the principle that turns a bewildering set of monoclonal kidney diseases into one coherent approach.

Five fully-built tables.

Table A — The unifying concept and MGRS

Table B — The spectrum of lesions

Table C — Detecting the paraprotein

Table D — Biopsy and diagnosis

Table E — Treatment

Visualise & Map

Causal chains, each ending in a named action.

Chain 1 — One source, many injuries

A clonal population produces a monoclonal protein → several distinct renal injuries → kidney disease → ACTION: treat the clone (MGRS), whatever the tumour burden.

Chain 2 — The obstructing cast

A flood of free light chains → precipitation with Tamm-Horsfall protein in the distal tubule → obstructing casts → AKI (myeloma kidney) → ACTION: urgently reduce the light chains (anti-myeloma).

Chain 3 — The fibril

Light chains misfold into fibrils → Congo-red-positive amyloid deposits → nephrotic syndrome → ACTION: treat the clone (and confirm with Congo red).

Chain 4 — The non-fibrillar deposit

Light chains deposit non-fibrillar along basement membranes → nodular glomerulosclerosis (light-chain deposition disease) → proteinuria/CKD → ACTION: treat the clone.

Chain 5 — The cryoglobulin

Cryoglobulins (monoclonal/mixed, often hepatitis-C-associated) → immune-complex MPGN with low complement → cryoglobulinemic GN → ACTION: treat the cause (hepatitis C / the clone).

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Five cases. Each stops you at a decision before it answers it.

Every mechanism from Level 3 earns a bedside consequence and an action.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Paraprotein kidney disease workup note

• Renal presentation: AKI / nephrotic / nodular sclerosis / MPGN ___.
• Paraprotein: SPEP/UPEP; immunofixation; serum free light chains (κ/λ) ___.
• Bone marrow / clone characterisation: ___.
• Biopsy lesion: cast / amyloid (Congo red) / LCDD / cryo / other; light-chain restriction ___.
• MGRS confirmed (lesion derives from the clone)? ___.

Template 2 — Clone-directed treatment / co-management note

• Clone type: plasma-cell vs B-cell / lymphoplasmacytic ___.
• Clone-directed therapy: anti-plasma-cell (bortezomib-based) / anti-B-cell (rituximab-based) ___.
• Cast nephropathy: urgent anti-myeloma; hydration; nephrotoxins stopped; hypercalcemia treated ___.
• Cryoglobulinemic GN: hepatitis C antivirals / clone / IS / plasma exchange ___.
• Haematology co-management; free-light-chain response monitored ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Nine items, each anchored in this chapter. At least one per objective.